Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helsinn Group has signed a distribution and license agreement with Stendhal for anamorelin, a once daily drug being developed against cachexia-anorexia associated with non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
According to the deal, Stendhal is responsible for regulatory/clinical development and commercialization activites of the phase III ghrelin receptor agonist in Mexico, Venezuela, Colombia, Peru, Ecuador and many other Central American countries.
Helsinn is responsible for CMC, preclinical and clinical development activities and anamorelin supply for commercial purpose.
Helsinn CEO Dr. Riccardo Braglia said, "With this new partnership we are further expanding our anamorelin franchise in America and we are achieving this through Stendhal and its really top quality team."
Phase II trials demonstrated anamorelin’s ability to improve appetite, increase lean body mass in people suffering from cancer-related anorexia-cachexia.
Stendhal CEO Carlos Arenas Wiedfeldt said, "Anamorelin will be an important part of our continued expansion in oncology in Latin America."